| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_004c67d96f1f67dc01e0bcbef1301e52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56579dc11eeeac79a99339e3a8b0e8c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc9c26315c83339864690d55d62c9c5b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0ae242d41bb140dec95e4e58c50a9ac5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate |
2010-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8a8b68fdd340fda226a1906a6a76902
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5831b5a2aa049bd493b7f904b1dc3500
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49dcf1d4709fac852af488045adc912f |
| publicationDate |
2011-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2011054030-A1 |
| titleOfInvention |
Treatment of cancer involving mutated kras or braf genes |
| abstract |
The present invention provides a method of treating cancer in a subject wherein the cancer comprises mutated KRAS or BRAF genes. The method comprises administering to the subject an effective amount of an antibody or antigen binding fragment thereof wherein the antibody or antigen binding fragment thereof competes with SC104 for binding to the human colon cancer cell line Colo205. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013155077-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014052613-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014052613-A3 |
| priorityDate |
2009-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |